Page last updated: 2024-12-06
cefadroxil
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
uvaricin: isolated from Uvaria accuminata; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 441645 |
CHEBI ID | 9916 |
SCHEMBL ID | 5881208 |
MeSH ID | M0003714 |
Synonyms (12)
Synonym |
---|
ygw6mn47bb , |
uvaricin |
chebi:9916 , |
[(1s)-1-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxy-13-[(2s)-2-methyl-5-oxo-2h-furan-4-yl]tridecyl]oxolan-2-yl]oxolan-2-yl]undecyl] acetate |
SCHEMBL5881208 |
Q2481797 |
2(5h)-furanone, 3-((13r)-13-((2r,2r,5r,5r)-5-((1s)-1-(acetyloxy)undecyl)octahydro(2,2-bifuran)-5-yl)-13-hydroxytridecyl)-5-methyl-, (5s)- |
2(5h)-furanone, 3-(13-(5-(1-(acetyloxy)undecyl)octahydro(2,2-bifuran)-5-yl)-13-hydroxytridecyl)-5-methyl-, (2r-(2.alpha.(2r*,5r*(s*)),5.beta.(r*(s*))))- |
(+)-uvaricin |
(1s)-1-[(2r,2'r,5r,5'r)-5'-[(1r)-1-hydroxy-13-[(5s)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]tridecyl]-[2,2'-bioxolan]-5-yl]undecyl acetate |
145165-09-9 |
DTXSID501043967 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
polyketide | Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID340563 | Antitumor activity against mouse P388 cells in at 1.4 mg/kg by in vivo 3PS assay | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Paw paw and cancer: annonaceous acetogenins from discovery to commercial products. |
AID335294 | In vivo antitumor activity against mouse 3PS cells at 1.4 mg/kg relative to control | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (33.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Clinical Trials (12)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers [NCT02381470] | Phase 2 | 58 participants (Actual) | Interventional | 2019-02-11 | Completed | ||
A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers [NCT02140281] | Phase 1 | 71 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868] | Phase 4 | 135 participants (Anticipated) | Interventional | 2023-08-04 | Enrolling by invitation | ||
A Two-Way , Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects. [NCT00835081] | Phase 1 | 26 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection [NCT04723940] | Phase 3 | 308 participants (Anticipated) | Interventional | 2021-01-25 | Enrolling by invitation | ||
A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation [NCT00405158] | 210 participants | Interventional | 2002-01-31 | Completed | |||
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction [NCT01244698] | Phase 4 | 132 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
A Two-Way Crossover, Open-Label, Single-Dose Fasting, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-smoking Male and Female Subjects. [NCT00834275] | Phase 1 | 26 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients [NCT04297592] | Phase 4 | 4,618 participants (Anticipated) | Interventional | 2020-06-11 | Enrolling by invitation | ||
Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated [NCT02446496] | Phase 4 | 24 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
Comparative Pharmacokinetics and Pharmacodynamics (PK/PD) of Cefadroxil and Cephalexin for Pediatric Musculoskeletal (MSK) Infections [NCT03802552] | Phase 1 | 17 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma) [NCT02479867] | Phase 1 | 24 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |